- Policy
- Will Rosuvastatin OD be released?
- by Lee, Tak-Sun Jun 30, 2021 05:55am
- Attention is focusing on whether a treatment for hyperlipidemia, Rosuvastatin OD (Orally Disintegrated Tablet) will be released. Rosuvastatin OD was approved in Japan in 2016, but has not yet been released in Korea. According to industries on the 25th, BCWORLD Pharm recently applied for approval of Rosuvastatin OD to the MFDS. Astra
- Company
- Amitiza can be prescribed at general hospitals
- by Eo, Yun-Ho Jun 29, 2021 05:46am
- Amitiza, a chronic constipation drug, can be prescribed at general hospitals. According to related industries, Amitiza(Lubiprostone), which is conducting exclusive promotion activities in Korea through contracts with Takeda Pharmaceuticals, passed the drug committee (DC) of 42 medical institutions nationwide, including AMC and Severance Ho
- Company
- Select the right initial treatment for kidney cancer
- by Jun 29, 2021 05:46am
- Cancer immunotherapies are receiving the spotlight in the treatment of kidney cancer. Demonstrating superiority over existing therapies, these drugs are quickly gaining ground in the field of kidney cancer treatment. Recently, MSD’s cancer immunotherapy ‘Keytruda (pembrolizumab) received approval as first-line treatment in combination with
- Policy
- Janssen Vaccine for 10,800 people has been approved
- by Lee, Tak-Sun Jun 29, 2021 05:46am
- The MFDS said it approved the nation lot release on the 25th (Friday) for 108,800 people of "Covid-19 Vaccine Janssen" applied by Janssen Korea. Nation lot release is a system in which the state checks the quality of the vaccine once again before it is distributed on the market by comprehensively evaluating the MFDS' test results of the va
- Policy
- Leclaza was listed at ₩68,964 per tablet
- by Kim, Jung-Ju Jun 29, 2021 05:46am
- Leclaza 80mg (Lazertinib) made with domestic technology passed the final step to insurance benefits. Leclaza finally chose this track, considering its similar clinical utility to the alternative drug Tagrisso, but cheaper with the Risk Sharing Agreement (RSA) Refund and Expenditure Cap. The date will be started on July 1, which means that
- Company
- Attention focused on children’s NIP flu vaccine supply
- by Whang, byung-woo Jun 29, 2021 05:46am
- With the bid for the 8 million doses of influenza vaccine for seniors under the National Immunization Program nearly compete, the pharmaceutical industry is intently focused on the supply amount and bid that will be set for the children’s NIP flu vaccines that will follow. According to the Korea Disease Control and Prevention Agency and the
- Policy
- Following Gilead's hepatitis C tx Epclusa, Vosevi was filed
- by Lee, Tak-Sun Jun 28, 2021 05:50am
- This year, hepatitis C drugs Epclusa and Vosevi have been filed by the MFDS in Korea. These items are expected to replace Sovaldi. According to the industry on the 27th, Gilead's Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) has recently been filed and will begin screening in earnest. Vosevi is expected to be a Pangenotypic DAA preparation
- Policy
- 16 drugs including Venclexta receive reimbursement in 1H
- by Kim, Jung-Ju Jun 28, 2021 05:50am
- A total of 14 products were newly listed on the insurance benefit list to improve patient access in the first half of this year. Also, two drugs benefited from the reimbursement criteria expansion that was applied to already-listed new drugs. This expanded coverage is interpreted as a result of the government’s decision to flexibly apply covera
- Company
- MET inhibitor ‘Tabrecta’ to overcome Tagrisso resistance?
- by Jun 28, 2021 05:50am
- A study that attempts to address the resistance issue by using the first-ever MET inhibitor ‘Tabrecta’ in combination with the EGFR-TKI ‘Tagrisso,’ will be conducted in Korea. According to the Ministry of Drug and Food Safety on the 25th, Novartis Korea’s application to conduct a Phase III trial on its non-small cell lung cancer trea
- Policy
- Billing for α-GPC is managed
- by Lee, Jeong-Hwan Jun 28, 2021 05:50am
- The HIRA plans to consider the need to manage claims by selecting Choline alfoscerate, which is under controversy over reducing adaptation certificates, as the "selection focused item." The MFDS plans to periodically monitor pharmaceutical companies that have been clinically reassessed, block unnecessary clinical extensions, and take ad
